Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027
Benzinga Newsdesk 1 week ago
News
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGOAdditionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027
- Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO
- Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027